ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir rilpivirine regimen

ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir, rilpivirine regimen

These two studies met their primary endpoints, showing that the combination of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine, injected every four weeks, was non-inferior in maintaining viral suppression

More From BioPortfolio on "ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir, rilpivirine regimen"